ICU MEDICAL INC/DE: insider trades · United States · SEC (Form 4)

About ICU MEDICAL INC/DE

ICU Medical, Inc. (ticker: ICUI) is a U.S.-based medical technology company listed on the NASDAQ in the United States. Headquartered in San Clemente, California, and founded in 1984, the company develops, manufactures, and sells products used in infusion therapy, vascular access, and critical care settings across hospitals, alternate-site care, and home-care environments. ([sec.gov](https://www.sec.gov/Archives/edgar/data/883984/000088398423000009/icui-20221231.htm?utm_source=openai)) From an operating perspective, ICU Medical is best understood as a specialized provider of infusion and hospital-based consumables and systems. Its product portfolio includes ambulatory, syringe, and large-volume IV pumps, safety software, dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, closed-system transfer devices for hazardous drugs, pharmacy compounding systems, and a range of respiratory, anesthesia, monitoring, and temperature-management products. This breadth makes the company relevant to a wide set of clinical workflows rather than a single product niche. ([ir.icumed.com](https://ir.icumed.com/?utm_source=openai)) ICU Medical’s strategic profile has been shaped by acquisitions and portfolio actions. The 2022 acquisition of Smiths Medical broadened its platform and added scale in infusion and critical care. More recently, the company completed a transaction in April 2025 that transferred its IV Solutions business into a joint venture with Otsuka Pharmaceutical Factory America, reflecting a deliberate move to reshape the portfolio and focus on higher-value categories. That transition is important for investors because it changes the revenue mix and the operational emphasis of the company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/883984/000088398425000035/icui-20250930.htm?utm_source=openai)) In competitive terms, ICU Medical holds a recognized position in infusion systems and consumables, where hospital customers value product reliability, clinical safety, and supply continuity. The company benefits from an integrated offering and an installed customer base, but it competes in a demanding global market against larger diversified medtech players. Its differentiation lies in specialization, breadth of consumables, and its ability to bundle devices, software, and workflow-oriented solutions. ([ir.icumed.com](https://ir.icumed.com/?utm_source=openai)) Recent developments have centered on the post-integration evolution of the business, product-line demand trends, and the ongoing repositioning of the portfolio following the IV Solutions divestiture into a joint venture. For equity investors, ICUI remains a healthcare industrial story tied to hospital utilization, integration execution, and management’s ability to optimize the mix toward systems, consumables, and critical-care categories. ([ir.icumed.com](https://ir.icumed.com/node/20516/pdf?utm_source=openai))